PreciseInhale is unique within inhaled drug development as a `precision dosing' system. Unlike standard `tower testing' systems, it customizes the individual aerosol dose to individual test animals, achieving exceptionally high-precision and predictive data in the preclinical stages of inhaled drug development.

ISAB has recently increased the focus of its commercial activities around its Inhalation Research Services (IRS) capabilities. Nevertheless, the company's unique platform still attracts direct purchase interest, often from academic research organizations looking to be able to offer state-of-the-art testing and data.

ISAB CEO Manoush Masarrat: "We have been working to finalize this deal for a while with our distributor and it is great to see it come to fruition. We are delighted to expand our presence in a region as exciting and dynamic as Asia. We look forward to seeing the work that will come out of this purchase."

Find out more about PreciseInhale here. (https://www.inhalation.se/products/)